RT Journal Article
SR Electronic
T1 PS-003 Safety and economic outcome after implementation of a restricted use antibiotic protocol
JF European Journal of Hospital Pharmacy
JO Eur J Hosp Pharm
FD British Medical Journal Publishing Group
SP A215
OP A216
DO 10.1136/ejhpharm-2016-000875.488
VO 23
IS Suppl 1
A1 E Tevar
A1 A De León-Gil
A1 JC Febles
A1 T Betancor-Garcia
A1 I Plasencia-Garcia
A1 MA Ocaña-Gomez
A1 S Ramos-Linares
A1 P Díaz
A1 E Marqués
A1 J Merino
YR 2016
UL http://ejhp.bmj.com/content/23/Suppl_1/A215.2.abstract
AB Background In 2013, our protocol of restricted use antibiotics (RUA) was updated and computerised.The following drugs were subject to their respective indications. Ertapenem: community intra-abdominal infection with risk factors, moderate or severe diabetic foot infections and outpatient management. Linezolid: pneumonia, diabetic foot infections, osteomyelitis and prosthetic infections, and serious bile duct infections. Daptomycin: endocarditis, diabetic foot infections, osteomyelitis and prosthetic infections, and right sided endocarditis. Tigecycline: complicated intra-abdominal infections or soft tissue infections, except diabetic foot infections, if there is no alternative.Purpose To evaluate RUA outcomes 1 year after implementation.Material and methods Computerised orders received in 2013; retrospective analysis.Results 500 requests for RUA were conducted: 22% ertapenem, 37.2% linezolid, 35.2% daptomycin and 5.6% tigecycline. The antibiotics were used as follow: ertapenem: intra-abdominal infections in 50.91%, diabetic foot infections 15.45%, peritonitis 9.1% and 27 patients (24.54%) to promote outpatient management.Linezolid: 32.26% skin and soft tissue infections, 30.12% pneumonia, 13.5% biliary tract infections, 9.6% osteomyelitis and prosthesis infections and 6.99% in diabetic foot infections.Daptomycin: 42.61% in infections of skin and soft tissues, 18.79% in bacteraemia, 13.07% in endocarditis, 10.8% in biliary tract infections; for hospital management, osteomyelitis and prosthetic infections, and diabetic foot infections were requested in 13.7% and 6%, respectively. Tigecycline: 11 cases of intra-abdominal infection and 17 skin and soft tissue infections.The RUA spending in 2013 compared with the previous year decreased by €31 843. Daptomycin increased slightly (€1461) while consumption of tigecycline and ertapenem was reduced by €14 254 and €13 131, respectively. This was a 45.7% and 31.5% reduction in costs over the previous year. Linezolid spending was also reduced €5920, slightly over (2%) the previous year.Conclusion The update and computerisation of the RUA protocol has achieved a reduction in spending on these antibiotics and improved adjustment of the prescriptions to the current indications for these drugs.References and/or Acknowledgements Hospital Computing Service.No conflict of interest.